How would you approach the management of a patient with Stage IV NSCLC harboring both a classical and non-classical compound EGFR mutations?

I was asked to dust off q prior Mednet discussion on frontline treatment selection for patients with a new diagnosis of advanced common EGFR mutation+ NSCLC in light of recent updates on both the key FLAURA2 and MARIPOSA trials. And indeed the timing seems ripe for such not just due to these updates but also the added complexity of emerging biomarkers for patients selection and a range of sequencing complexities in light of new/upcoming arrivals in the second line and beyond landscape, such as Dato-dxd , PD1/VEGF bispecifics or the COMPEL “regimen?

So what’s new? Just about a year ago we had butterflies learning about the OS outcomes from MARIPOSA-significant OS benefit for ami/lazer over osimertinib alone with a HR of 0.75 and a projected ...